The size of your meniscus matters: Knee pain explained

With all of the fantastic imaging techniques available in healthcare today, clinicians are capable of diagnosing tissue and joint deformities using non-invasive imaging with remarkable accuracy. However, one vexing question remains: why are some patients with specific joint deformities symptomatic while others are not?

The meniscus is a piece of cartilage that cushions the knee joint between the femur (thigh bone) and the tibia (shin bone). Some people are born with a congenital morphological variation in their meniscus, called a discoid lateral meniscus (DLM), where the meniscus is thickened on the lateral, or outer side of the knee. DLM malformations cause the lateral meniscus to form a circle rather than a crescent shape, thickening the cartilage and making it more prone to tears. Some patients develop symptoms such as knee pain and a locking, leading to surgery.

In order to better understand what factors separate symptomatic DLM cases from asymptomatic cases, a multi-institutional team of researchers led by Dr. Kazuya Nishino of the Graduate School of Medicine at Osaka Metropolitan University analyzed 61 knees with discoid lateral meniscus surgery without dislocation (symptomatic group) and 35 without symptoms but with discoid lateral meniscus detected on MRI (asymptomatic group). The percentage of meniscus was calculated in the coronal and sagittal sections, respectively. The researchers also measured the height of the thinnest and thickest part of the meniscus.

The results revealed that the percentage of the meniscus covering the tibia in the coronal and sagittal planes was higher in the symptomatic group than in the asymptomatic group. Additionally, the results showed that the meniscal height was greater in the symptomatic group than in the asymptomatic group.

Overall, preoperative imaging is helpful in determining the amount of tissue resection, or removal, required for patients with symptomatic DLM. “Making surgical decisions and plans based on these characteristics is expected to assist in medical treatment. In the future, we will investigate the morphological changes of the meniscus before and after surgery in three dimensions,” said Dr. Nishino.

While the difference in the morphologies of symptomatic vs. asymptomatic DLMs was the most important finding in the study, the MRIs of symptomatic patients also showed meniscal tears or other evidence of instability. The researchers suggest that these morphological features could be responsible for DLM symptoms in symptomatic patients.

Reference:

Kazuya Nishino, Yusuke Hashimoto, Takuya Kinoshita, Ken Iida, Shuko Tsumoto, Hiroaki Nakamura, Comparative analysis of discoid lateral meniscus size: a distinction between symptomatic and asymptomatic cases, Knee Surgery Sports Traumatology Arthroscopy, https://doi.org/10.1007/s00167-023-07650-2.

Powered by WPeMatico

Can inflammation related diseases increase risk of primary acquired nasolacrimal duct obstruction?

Primary Acquired Nasolacrimal Duct Obstruction (PANDO) has long been a concern for patients, impacting their ocular health. A recent retrospective case-control study conducted by Clalit Health Services in Israel delves into the intricate associations between PANDO and various inflammatory conditions. The findings shed light on the multifaceted nature of PANDO, revealing significant connections with ocular surface, eyelid, upper airway, and systemic inflammatory-related diseases.

This study was published in the journal Graefe’s Archive for Clinical and Experimental Ophthalmology by Kerber and colleagues. To evaluate the incidence and risk factors for inflammatory conditions among patients with PANDO. 60,726 patients diagnosed with PANDO, with an average age of 63 years, 63% female. A case-control approach matching controls according to year of birth, sex, and ethnicity.

The key findings of the study were:

Ocular Surface and Eyelid Conditions:

  • Chronic conjunctivitis showed a significant association with PANDO (OR 2.96).

  • Vernal keratoconjunctivitis and blepharitis exhibited notable connections (OR 2.89 and 2.75, respectively).

Upper Airway Conditions:

  • Rhinitis, chronic sinusitis, and deviated nasal septum were significantly associated with PANDO (OR 1.62, 1.71, and 1.76, respectively).

Systemic Conditions:

  • Asthma and atopic dermatitis showed significant associations with PANDO (OR 1.34 and 1.36, respectively).

This comprehensive study underscores the intricate relationship between PANDO and inflammatory-related diseases affecting the ocular surface, eyelids, upper airway, and systemic health. The identified associations provide valuable insights into the pathophysiology of PANDO, emphasizing the role of inflammation. Recognizing these links can contribute to a more holistic understanding of PANDO and guide clinicians in developing tailored management strategies.

Reference:

Kerber, L., Kerman, T., Hazan, I., Ziv, O., Kordelul, S., & Tsumi, E. Are inflammation-related diseases risk factors for primary acquired nasolacrimal duct obstruction? A large scale, national case-control study. Graefe s Archive for Clinical and Experimental Ophthalmology,2024. https://doi.org/10.1007/s00417-023-06352-2

Powered by WPeMatico

Private Medical Colleges Failing Students Deliberately, charging additional fees for repeating semester: Parliamentary Panel

New Delhi: Some of the private medical colleges have been deliberately failing medical students during mid-semester exams and charging additional fees for repeating the semester or the exam, a Parliamentary panel recently observed in its report.

The Department-related Parliamentary Standing Committee on Health and Family Welfare further opined in its One Hundred Fifty-Seventh Report that the Undergraduate Medical Education Board (UGMEB) of NMC may develop appropriate feasible modalities to monitor assessment, revaluation, etc. without charging any additional fee.

Chaired by Shri Bhubaneswar Kalita, the panel presented its report before the Parliament on 9th February 2024. Several issues related to medical education such as infrastructure, faculty issues, and quality control of medical education were discussed in the report.

The Committee was apprised of the fact that some private medical colleges seemingly fail medical graduates deliberately during mid-semester exams which results in repetition of the semester, and charging additional fees for repeating the semester or exam.

Referring to the issue, the Parliamentary Panel on Health observed that such a practice causes stress on the medical students – financial and otherwise.

Therefore, advising the Apex Medical Commission to set up proper feasible modalities to monitor assessment and evaluation process, the panel mentioned in its report, “The Committee therefore recommends that UGMEB may develop appropriate feasible modalities for monitoring assessment, revaluation, etc. without charging any additional fee.”

The average MBBS course fees across Government colleges in India (both centrally funded, and State Government funded) can reach 50,000 per annum. However, such subsidized medical education can only be availed by a select few who perform exceedingly well in the NEET UG exam, noted the panel.

It further highlighted that as per the information furnished by the Union Health Ministry, there are only 56,193 Government seats in MBBS and as per NTA, more than 11 lakh candidates qualified for the NEET UG exam in 2023. Therefore, more than 10 lakh MBBS aspirants are left either to opt for MBBS seats in private medical colleges where the course fees can range up to 1.5 crores or to pursue their dream in countries like China, Ukraine, and Russia, where the cost is lower in comparison to private colleges in India.

NMC Fee Order: 

Medical Dialogues had earlier reported that back in 2022, the National Medical Commission issued a direction to all the private medical colleges in the country to charge fees at par with the government institutes for 50 per cent of the total seats.

Issuing an Office Memorandum in February 2022, NMC mentioned, “After extensive consultations, it has been decided that the fee of the 50 per cent seats in the private medical colleges and deemed universities should be at par with the fee in the government medical colleges of that particular State and UT. The benefit of this fee structure would be first made available to those candidates who have availed government quota seats, but are limited to the extent of 50 per cent of the total sanctioned strength of the respective medical college/deemed university.”

“However, if the government quota seats are less than 50 per cent of total sanctioned seats, the remaining candidates would avail the benefit of a fee equivalent to the government medical college fees, based purely on the merit,” the Commission had added.

The validity of the NMC order has time and again been challenged before various High Courts and also Supreme Court, where AHSI challenged the order arguing that the top court in various judgments had reiterated the fact that the method for fixing the fees, would be subject to considering various guidelines such as facilities available in the college, infrastructure, age of investment made, plans for expansion, etc.

Currently, the validity of the NMC fee order is being considered by the Supreme Court and all the connected matters in this regard has been listed for further hearing on 22nd March, 2024.

Meanwhile, the Parliamentary Panel has also recommended that NMC should undertake a comparative study of best practices of its parallel organisation in various countries. The Parliamentary Committee opined that if such a study is undertaken by NMC, it can help the Commission to usher in best practices followed around the world and help make NMC an institution par excellence.

Also Read: Flexner Model: Parliamentary Panel Advises NMC to Study International Best Practices

Powered by WPeMatico

New Vaccine shows promise against cytomegalovirus

An experimental mRNA vaccine against human cytomegalovirus (CMV), a common virus that can infect babies during pregnancy, elicited some of the most promising immune responses to date of any CMV vaccine candidate, according to a study by Weill Cornell Medicine investigators.

The study, published in the Journal of Infectious Diseases on Feb. 7, provided evidence that the new mRNA vaccine candidate, which is manufactured by Moderna, Inc., may protect adults against CMV. Thus, it could potentially prevent women from passing the harmful infection to their babies during pregnancy. Compared with a previous moderately successful vaccine candidate called gB/MF59, the mRNA vaccine elicited responses that were better at preventing the CMV virus from infecting epithelial cells that line the mouth and nose and provide the first line of defense against viral infection. The mRNA vaccine was also more effective at triggering the immune system to destroy CMV-infected cells.

“We learned that the newer vaccine has the potential to be more effective than a previous CMV vaccine candidate because some of the functional immune responses it elicits are higher in magnitude,” said senior author Dr. Sallie Permar, the chair of the Department of Pediatrics and Nancy C. Paduano Professor in Pediatrics at Weill Cornell Medicine. “An ongoing clinical trial will confirm if those differences lead to greater protection against CMV infection.”

Though healthy adults are largely asymptomatic, one in every 200 newborns worldwide are infected with CMV during their mother’s pregnancy. The virus rarely causes serious illness in healthy adults, but it can cause birth defects and brain damage in newborns infected in utero and deadly infections in immune-compromised adults.

“It is the most common congenital infection worldwide,” explained Dr. Permar, who is also pediatrician-in-chief at NewYork-Presbyterian/Weill Cornell Medical Center and NewYork-Presbyterian Komansky Children’s Hospital.

Co-first authors Dr. Krithika P. Karthigeyan, postdoctoral associate in pediatrics at Weill Cornell Medicine, and Dr. Xintao Hu, who was part of the research team at the time, also contributed to this research.

CMV Vaccine Candidates

Previously, Sanofi and Novartis had developed vaccine candidate gB/MF59, which targeted glycoprotein B (gB), a sugar-laden viral surface protein that works with other proteins to help CMV attach to and enter human cells. It protected about half of vaccinated individuals from CMV infection in a phase 2 clinical trial led by the National Institute of Allergy and Infectious Diseases Vaccine Clinical Trials Network. When the trial ended in 2013, it did not progress to phase 3 clinical trials.

Dr. Permar and her colleagues used the data and patient samples from the gB/MF59 phase 2 trial in adolescent girls as a benchmark to assess the new mRNA-based vaccine. Using the same technology that produced the company’s COVID-19 vaccine, Moderna’s CMV vaccine added a second target—a five-unit protein complex that allows the virus to infect the epithelial cells that line the nose and mouth-in addition to glycoprotein B.

In this study, Dr. Permar and her team compared the immune responses of individuals vaccinated with gB/MF59 in the phase 2 trial with those immunized with Moderna’s mRNA-based CMV vaccine in a phase 1 clinical trial which ended in 2020. Specifically, the team compared the immune responses in people who were protected against CMV infection after receiving the older vaccine.

New Vaccine Triggers Stronger Immune Response

The mRNA vaccine-likely because of the additional second target-did a better job of preventing the CMV virus from infecting healthy epithelial cells. The vaccine triggered immune cells to produce neutralizing antibodies that block the entry of the virus into a cell, which prevents viral replication. Also, the mRNA vaccine induced antibody responses that could destroy infected cells. In contrast, people vaccinated with the gB/MF59 vaccine produced higher levels of antibodies against gB that had low neutralizing activity but had strong ability to engulf and eliminate a virus.

The Moderna vaccine has moved on to the first ever phase 3 clinical study for a CMV vaccine candidate, which will help determine if these differences in immune responses will lead to stronger protection against CMV. “After more than 50 years of research, we are closer than ever to having a licensed CMV vaccine,” Dr. Permar said. “The new mRNA platform has a lot of potential.”

In the meantime, Dr. Permar and her colleagues have developed a preclinical model to test whether similar vaccines protect against fetal CMV transmission during pregnancy.

Reference:

Xintao Hu, Krithika P Karthigeyan, Savannah Herbek, Sarah M Valencia, Jennifer A Jenks, Helen Webster, Itzayana G Miller, Megan Connors, Justin Pollara, Caroline Andy, Linda M Gerber, Emmanuel B Walter, Kathryn M Edwards, David I Bernstein, Jacob Hou, Matthew Koch, Lori Panther, Andrea Carfi, Kai Wu, Sallie R Permar, Human Cytomegalovirus mRNA-1647 Vaccine Candidate Elicits Potent and Broad Neutralization and Higher Antibody-Dependent Cellular Cytotoxicity Responses Than the gB/MF59 Vaccine, The Journal of Infectious Diseases, 2024;, jiad593, https://doi.org/10.1093/infdis/jiad593.

Powered by WPeMatico

Dr Mansukh Mandaviya unveils AIIMS SBI Smart Payment Card

Union Minister for Health & Family Welfare and Chemicals & Fertilizers, Dr Mansukh Mandaviya has launched the AIIMS SBI Smart Payment Card. The AIIMS SBI Smart Payment Card will ensure hassle-free payments for treatment in AIIMS New Delhi.

Speaking on the occasion, the Union Health Minister highlighted that the “AIIMS Smart Payment Card will resolve the long pending issue of patients from far-flung areas carrying cash with them to the hospital.” He added that patients or their caretakers can get the card easily from the facilitation centres across AIIMS, New Delhi and thereafter use it for payment at various counters.

For the full story, check out the link given below:

One AIIMS, One Card: Union Health Minister Launches AIIMS-SBI Smart Card For Cashless Payments

Powered by WPeMatico

ICU Rat Bite Case: Telangana doctors protest against suspension of two doctors, nurse

Hyderabad: In response to the suspension of the two on-duty doctors and a nursing staff following an incident where a patient was bitten by rats in the ICU of Kamareddy Government Hospital. The doctors across Telangana protested and demanded the order be revoked. 

After a patient was bitten by rats on his fingers and toes while he was undergoing treatment at the Kamareddy government hospital, two doctors and a nursing staff were suspended on Sunday due to allegations of being negligent towards the patient.

The three employees in the Intensive Care Unit (ICU) at Government Medical College and General Hospital, Kamareddy, faced disciplinary action after an investigation conducted by Vaidya Vidhana Parishad commissioner Ajay Kumar uncovered alleged medical negligence on their part.

The patient was undergoing treatment at the government hospital at Kamareddy district headquarters. According to hospital officials, he had undergone decompressive craniotomy surgery at NIMS, Hyderabad on January 21. He was later admitted to Kamareddy Hospital and was on ventilator support.

Also read- Rodents Menace: SMS Hospital Engages Firm To Prevent Infection

However, the situation turned serious when the patient was bitten by rats on his hands and feet in the ICU on February 9. After noticing the scars on his fingers and toes, the family members filed a complaint to the hospital authorities. 

In response to the complaint, a preliminary investigation was launched and the probe held that these three employees who were on night duty were responsible for the matter asserting that they were negligent in taking care of the patient, reports TOI. 

Kamareddy district collector Jitesh V. Patil ordered the suspension of ICU in-charge general medicine Dr Vasanth Kumar (Associate Professor), ICU in-charge Dr Kavya (Assistant Professor) and nursing officer. The district collector also surrendered the services of the hospital superintendent to the government, IANS reports.

Meanwhile, doctors and hospital employees on Monday staged a protest over the suspension of three colleagues. Wearing black badges, doctors participated in the protest in front of the hospital. Not only this, doctors from government hospitals across the state, including Mancherial, Jangaon, Nirmal, Ramagundam, Mahabubnagar, Wanaparthy and Asifabad, among others also expressed their displeasure with the government’s decision. They demanded that the suspension be revoked and threatened to go on strike if the suspension was not lifted.

Condemning the suspension of the doctors, the Telangana Teaching Government Doctors’ Association (TTGDA) said that the doctors were concerned only till they treated the patients and it was the responsibility of sanitation staff and officials to keep the hospital free from rats, dogs, pigs and insects.

Following this, the association had a meeting with Health Minister Damodar Raja Narasimha on Monday evening. The Minister assured the protesting doctors that the suspension order would be revoked and action would be initiated against appropriate authorities.

Dr Jalagam Thirupathi Rao, the State General Secretary of the Telangana Teaching Government Doctors Association (TTGDA) told TH, “The responsibility for rodent-related issues lies with the sanitation staff and not the doctors. The required action should be directed towards the sanitation agency, not the doctors who have no involvement in sanitation matters. We are staging a black badge protest, urging the DME to revoke the suspensions; otherwise, all doctors in the State will march to the DME office on Tuesday.”

Among those suspended Dr Vasanth Kumar informed the Daily that he was not present at the hospital on the day of the incident. “From February 9 until now, I have been assigned duties as an external examiner at Gandhi Medical College Hyderabad. Secondly, nobody ever made me in charge of the ICU at the Kamareddy Hospital. How can they suspend me when I was not present during the time of the incident?” he added.

Similarly, Dr Kavya said that she was not responsible for the incident as she had morning duty and denied being the ICU in-charge as mentioned in the government release.

Meanwhile, the Indian Medical Association (IMA) also came in support of the protesting doctors and threatened to hold a statewide protest if the government fails to revoke the suspension of the three employees. 

The association in a statement said, “It is the duty of all medical officers to treat the patient till they are discharged, but they have no role in searching for rats in the wards to prevent bites. The ICU is meant to extend treatment to serious patients, to save precious lives. But, not to keep vigil on rats. It is highly irresponsible and unprofessional action taken against the medical officer for rate bite.”

Later, Telangana Vaidhya Vidhana Parishad commissioner Ajay Kumar visited the hospital and inspected with a three-member committee based on the direction of the Health Minister. During the inspection, the committee found several lapses in the hospital and recommended revoking the suspension of the three employees. 

“The hospital has several lapses, including staff crunch, improper upkeep and ongoing construction work. Sightings of rats have been common. The hospital was converted into a medical college last year and is being upgraded from a 100-bed hospital to a 300-bed one. There is sewer network work going on too,” a source told TOI. 

“The government general hospital in Kamareddy has a capacity of 10 ICU beds. The rodent problem is due to dismantling work beside the ICU for renovation of the dialysis unit as well as because of food thrown by patients’ attendants,” a statement issued by the Department of Health, medical and Family Welfare stated. It added that the department was monitoring the situation and “no untoward incident will be tolerated, especially in offering health care to the needy”. As a result, a departmental inquiry has been ordered by the government in this regard. 

Attendants of other patients also complained about the rat menace at the hospital. They demanded hospital authorities to take immediate action to solve the problem.

Also read- Rodents Menace At Prayagraj Hospital: Allahabad HC Takes Suo Motu Cognizance

Powered by WPeMatico

Salt substitutes help maintain healthy BP without risk of hypotension among elderly

Researchers have found in a new study that replacement of regular salt with a salt substitute can reduce incidence of high blood pressure, in older adults without increasing their risk of low blood pressure episodes. Further people who used a salt substitute had a 40% lower incidence and likelihood of experiencing hypertension compared to those who used regular salt.

The study has been published in Journal of the American College of Cardiology. 

According to the World Health Organization, hypertension is the leading risk factor for cardiovascular disease and mortality. It affects over 1.4 billion adults and results in 10.8 million deaths per year worldwide. One of the most effective ways to reduce hypertension risk is to reduce sodium intake. This study looks at salt substitutes as a better solution to control and maintain healthy blood pressure than reducing salt alone.

“Adults frequently fall into the trap of consuming excess salt through easily accessible and budget-friendly processed foods,” said Yangfeng Wu, MD, PhD, lead author of the study and Executive Director of Peking University Clinical Research Institute in Beijing, China. “It’s crucial to recognize the impact of our dietary choices on heart health and increase the public’s awareness of lower-sodium options.”

Researchers in this study evaluated the impact of sodium reduction strategies on blood pressure in elderly adults residing in care facilities in China. While previous studies prove that reducing salt intake can prevent or delay new-onset hypertension, long-term salt reduction and avoidance can be challenging.

The DECIDE-Salt study included 611 participants 55 years or older from 48 care facilities split into two groups: 24 facilities (313 participants) replacing usual salt with the salt substitute and 24 facilities (298 participants) continuing the use of usual salt. All participants had blood pressure <140/90mmHg and were not using anti-hypertension medications at baseline. The primary outcome was participants who had incident hypertension, initiated anti-hypertension medications or developed major cardiovascular adverse events during follow-up.

At two years, the incidence of hypertension was 11.7 per 100 people-years in participants with salt substitute and 24.3 per 100 people-years in participants with regular salt. People using the salt substitute were 40% less likely to develop hypertension compared to those using regular salt. Furthermore, the salt substitutes did not cause hypotension, which can be a common issue in older adults.

“Our results showcase an exciting breakthrough in maintaining blood pressure that offers a way for people to safeguard their health and minimize the potential for cardiovascular risks, all while being able to enjoy the perks of adding delicious flavor to their favorite meals,” Wu said. “Considering its blood pressure – lowering effect, proven in previous studies, the salt substitute shows beneficial to all people, either hypertensive or normotensive, thus a desirable population strategy for prevention and control of hypertension and cardiovascular disease.”

Limitations of the study include that it is a post-hoc analysis, study outcomes were not pre-specified and there was a loss of follow-up visits in many patients. Analyses indicated that these missing values were at random, and multiple sensitivity analyses supports the robustness of the results.

In an accompanying editorial comment, Rik Olde Engberink, MD, PhD, researcher, nephrologist and clinical pharmacologist at Amsterdam University Medical Center’s Department of Internal Medicine, said the study provides an attractive alternative to the failing strategy to reduce the intake of salt worldwide, but questions and effort remain.

“In the DECIDE-Salt trial, the salt substitute was given to the kitchen staff, and the facilities were not allowed to provide externally sourced food more than once per week,” Olde Engberink said. “This approach potentially has a greater impact on blood pressure outcomes, and for this reason, salt substitutes should be adopted early in the food chain by the food industry so that the sodium-potassium ratio of processed foods will improve.”

Powered by WPeMatico

Akums Gets CDSCO Panel Nod To Manufacture, Market Antidiabetic FDC Drug

New Delhi: The drug major Akum Pharmaceutical has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to manufacture and market the fixed-dose combination (FDC) antidiabetic drug Dapagliflozin Propanediol Monohydrate Eq. to Dapagliflozin 5mg/5mg/5mg/5mg plus Glimepiride IP 1mg/2mg/1mg/2mg plus Metformin Hydrochloride IP (As ER) 500mg/500mg/1000mg/1000mg film coated bilayered tablet.

However, this approval is subject to the condition that Akum Pharmaceutical conduct an Active Postmarketing study (PMS).

This came after Akum Pharmaceutical presented their proposal along with a bioequivalence (BE) report of the higher strength of the proposed FDC (Dapagliflozin10mg + Glimepiride 2mg + Metformin ER 1000mgtablet) before the committee.

Dapagliflozin is in a class of medications called sodium-glucose co-transporter 2 (SGLT2) inhibitors. It lowers blood sugar by causing the kidneys to get rid of more glucose in the urine. Dapagliflozin is used along with diet and exercise, and sometimes with other medications, to lower blood sugar levels in adults with type 2 diabetes (a condition in which blood sugar is too high because the body does not produce or use insulin normally).

Glimepiride is a sulfonylurea class of drugs. Glimepiride is used to treat high blood sugar levels caused by type 2 diabetes. It may be used alone or in combination with insulin or another oral medicine such as metformin. In type 2 diabetes, insulin produced by the pancreas is not able to get sugar into the cells of the body where it can work properly.

Metformin, classified as a biguanide drug, effectively lowers blood glucose levels by decreasing glucose production in the liver, diminishing intestinal absorption, and enhancing insulin sensitivity. As a result, metformin effectively lowers both basal and postprandial blood glucose levels.

At the recent SEC meeting for Endocrinology and Metabolism held on 24th January 2023, the expert panel reviewed the proposal along with the BE report of higher strength of the FDC Dapagliflozin Propanediol Monohydrate plus Glimepiride plus Metformin Hydrochloride film-coated bilayered tablet.

After detailed deliberation, the committee recommended the grant of permission to manufacture and market the product after submission of data including dissolution data and justification for BE waiver as per the BE Study guideline with the condition that the firm should conduct Active PMS study.

Accordingly, the expert panel suggested that the firm should submit an active PMS study protocol to CDSCO within 03 months of approval for review by the committee.

Also Read: Study Safety and Efficacy of Tenecteplase 0.25 mg/kg in Acute Ischemic Stroke: CDSCO Panel Tells Boehringer Ingelheim

Powered by WPeMatico

Mohs Micrographic Surgery for skin cancer treatment introduced in AIIMS Delhi

Our skin serves as the body’s protective barrier, yet without proper care, it can become susceptible to serious conditions like cancer.

The global incidence of cancer, including skin cancer, is on the rise. Every month, the All India Institute of Medical Sciences (AIIMS), Delhi treats 5 to 6 patients with skin cancer.

To address this growing concern, AIIMS Delhi has introduced a new surgery for skin cancer treatment. Inaugurated by Professor M Srinivas, Director of AIIMS Hospital on Saturday, this new facility ensures that patients no longer need to seek treatment abroad.

For the full story, check out the link given below:

Delhi AIIMS Introduces Mohs Micrographic Surgery For Skin Cancer Treatment

Powered by WPeMatico

Doctors practising, studying in Bengal mandatorily require registration with West Bengal Medical Council

The medical practitioners who are employed in any capacity in West Bengal, those involved in private practice, or the Postgraduate students in any medical college in the State will now mandatorily require registration with the West Bengal Medical Council. This includes the doctors who have registrations in other states and are currently working in the state.

Issuing a notification in this regard on 09.02.2024, the Council further clarified that those who do not have registration with the West Bengal Medical Council will have to obtain the same within the coming three months.

For the full story, check out the link given below:

Registration Mandatory For All Doctors Practising, Studying In Bengal, Medical Council Gives Deadline

Powered by WPeMatico